Vaccines with interleukin-33 as an adjuvant

Abstract

Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.

What is claimed is: 
     
         1 . A vaccine comprising an antigen and IL-33. 
     
     
         2 . The vaccine of  claim 1 , wherein IL-33 is encoded by a nucleotide sequence selected from the group consisting of: a nucleotide sequence having at least about 95% identity to a nucleotide sequence as set forth in SEQ ID NO:1, a nucleotide sequence as set forth in SEQ ID NO:1, a nucleotide sequence having at least about 95% identity to a nucleotide sequence as set forth in SEQ ID NO:3, and a nucleotide sequence as set forth in SEQ ID NO:3. 
     
     
         3 . The vaccine of  claim 2 , wherein IL-33 is encoded by the nucleotide sequence as set forth in SEQ ID NO:1. 
     
     
         4 . The vaccine of  claim 2 , wherein IL-33 is encoded by the nucleotide sequence as set forth in SEQ ID NO:3. 
     
     
         5 . The vaccine of  claim 1 , wherein the antigen is encoded by a first nucleic acid and IL-33 is encoded by a second nucleic acid. 
     
     
         6 . The vaccine of  claim 5 , further comprising an antigen peptide with the same encoded nucleic acid sequence as the antigen of  claim 5 , and an IL-33 peptide with the same encoded nucleic acid sequence as the IL-33 of  claim 5 . 
     
     
         7 . The vaccine of  claim 1 , wherein IL-33 is selected from the group consisting of proIL-33 and mtrIL-33. 
     
     
         8 . The vaccine of  claim 7 , wherein IL-33 is proIL-33. 
     
     
         9 . The vaccine of  claim 8 , wherein proIL-33 is encoded by a nucleotide sequence as set forth in SEQ ID NO:3. 
     
     
         10 . The vaccine of  claim 7 , wherein IL-33 is mtrIL-33. 
     
     
         11 . The vaccine of  claim 10 , wherein mtrIL-33 is encoded by a nucleotide sequence as set forth in SEQ ID NO:1. 
     
     
         12 . The vaccine of  claim 1 , wherein the antigen is selected from the group consisting of: a human papilloma virus (HPV) antigen, an Human Immunodeficiency Virus (HIV) antigen, an influenza antigen, a  Plasmodium falciparum  antigen, a  Mycobacterium tuberculosis  antigen, a lymphocytic choriomeningitis (LCMV) antigen, and a fragment thereof. 
     
     
         13 . The vaccine of  claim 12 , wherein the HPV antigen is selected from the group consisting of: HPV16 E6 antigen, HPV16 E7 antigen, and a combination thereof. 
     
     
         14 . The vaccine of  claim 12 , wherein the HIV antigen is selected from the group consisting of: Env A, Env B, Env C, Env D, B Nef-Rev, Gag, and any combination thereof. 
     
     
         15 . The vaccine of  claim 12 , wherein the influenza antigen is selected from the group consisting of: H1 HA, H2 HA, H3 HA, H5 HA, BHA antigen, and any combination thereof. 
     
     
         16 . The vaccine of  claim 12 , wherein the  Plasmodium falciparum  antigen includes a circumsporozoite (CS) antigen. 
     
     
         17 . The vaccine of  claim 12 , wherein the  Mycobacterium tuberculosis  antigen is selected from the group consisting of: Ag85A, Ag85B, EsxA, EsxB, EsxC, EsxD, EsxE, EsxF, EsxH, EsxO, EsxQ, EsxR, EsxS, EsxT, EsxU, EsxV, EsxW, and any combination thereof. 
     
     
         18 . The vaccine of  claim 12 , wherein the LCMV antigen is selected from the group consisting of: nucleoprotein (NP), glycoprotein (GP), and a combination thereof. 
     
     
         19 . The vaccine of  claim 1 , further comprising a pharmaceutically acceptable excipient. 
     
     
         20 . The vaccine of  claim 5 , wherein the second nucleic acid further comprises an expression vector. 
     
     
         21 . A method for increasing an immune response in a subject in need thereof, the method comprising administering the vaccine of  claim 1  or  2  to the subject. 
     
     
         22 . The method of  claim 21 , wherein administering the vaccine includes electroporation. 
     
     
         23 . The method of  claim 21 , wherein the immune response in the subject is increased by at least about 2-fold. 
     
     
         24 . The method of  claim 23 , wherein the immune response in the subject is increased by at least about 4-fold. 
     
     
         25 . The method of  claim 21 , wherein increasing the immune response in the subject includes increasing a cellular immune response in the subject. 
     
     
         26 . A method for treating cancer in a subject in need thereof, the method comprising administering the vaccine of  claim 1  or  2  to the subject. 
     
     
         27 . The method of  claim 26 , further comprising reducing tumor size in the subject. 
     
     
         28 . The method of  claim 26 , further comprising increasing tumor regression in the subject. 
     
     
         29 . The method of  claim 26 , wherein the cancer is selected from the group consisting of: an HPV-associated cancer, an HBV-associated cancer, an ovarian cancer, a prostate cancer, a breast cancer, a brain cancer, a head and neck cancer, a throat cancer, a lung cancer, a liver cancer, a cancer of the pancreas, a kidney cancer, a bone cancer, a melanoma, a metastatic cancer, an hTERT-associated cancer, a FAP-antigen associated cancer, a non-small cell lung cancer, a blood cancer, an esophageal squamous cell carcinoma, a cervical cancer, a bladder cancer, a colorectal cancer, a gastric cancer, an anal cancer, a synovial carcinoma, a testicular cancer, a recurrent respiratory papillomatosis, a skin cancer, a glioblastoma, a hepatocarcinoma, a stomach cancer, an acute myeloid leukemia, a triple-negative breast cancer, and a primary cutaneous T cell lymphoma. 
     
     
         30 . The method of  claim 26 , wherein the cancer is the HPV-associated cancer. 
     
     
         31 . A nucleic acid molecule comprising one or more nucleotide sequences selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:3, a nucleotide sequence that is 95% identical or greater to SEQ ID NO:1, a nucleotide sequence that is 95% identical or greater to SEQ ID NO:3, and any combination thereof. 
     
     
         32 . The nucleic acid molecule of  claim 31 , wherein the nucleic acid molecule is a plasmid. 
     
     
         33 . The nucleic acid molecule of  claim 31 , wherein the nucleic acid molecule is one or more plasmids.